EGFR and non-small cell lung carcinoma: The Iressa Pan-Asia Study (IPASS) trial indicated that gefitinib was superior to carboplatin plus paclitaxel as an initial treatment for patients with advanced NSCLC harboring an EGFR mutation [8].